Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials

BACKGROUND: The significant morbidity and mortality resulted from the infection of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) call for urgent development of effective and safe vaccines. We report the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in heal...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Hong-Xing, Liu, Jian-Kai, Huang, Bao-Ying, Li, Gui-Fan, Chang, Xian-Yun, Liu, Ya-Fei, Wang, Wen-Ling, Chu, Kai, Hu, Jia-Lei, Li, Jing-Xin, Zhu, Dan-Dan, Wu, Jing-Liang, Xu, Xiao-Yu, Zhang, Li, Wang, Meng, Tan, Wen-Jie, Huang, Wei-Jin, Zhu, Feng-Cai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183795/
https://www.ncbi.nlm.nih.gov/pubmed/33928916
http://dx.doi.org/10.1097/CM9.0000000000001573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183795/
https://www.ncbi.nlm.nih.gov/pubmed/33928916
http://dx.doi.org/10.1097/CM9.0000000000001573

Ejemplares similares